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Case Presentation
KB, a 54-year-old previously healthy woman,
was referred to the University of California,
Davis, Occupational and Environmental
Medicine Clinic with a 2-year history of wors-
ening alopecia and memory loss. Her symp-
toms began in October 2002 with minor
memory loss and fatigue. Her primary care
physician conducted a thorough physical exam,
which showed no abnormality; all laboratory
studies (complete blood count, electrolytes,
thyroid-stimulating hormone) were also nor-
mal. KB’s physician believed her symptoms
were related to menopause. With no speciﬁc
diagnosis or treatment recommendations, our
patient started taking a variety of herbal thera-
pies including kelp supplement, ﬁsh oil, ginkgo
biloba, and grape seed extract. The kelp supple-
ment was the only herbal therapy taken regu-
larly throughout the course of her illness. She
initially took two tablets of Icelandic Kelp sup-
plement (Liminaria digitata) per day (41 mg
kelp, 66 mg calcium, 225 µg iodine). Over the
next few months, she subjectively noticed new
and progressively worsening symptoms. During
her exam, it was noted that her short- and long-
term memory had become impaired to the
point where she could no longer remember her
home address, a location where she had lived
for the previous 5 years. She also began having
difﬁculties functioning at work, where she did
intake for a mental health facility.
KB’s gynecologist believed her symptoms
were likely due to a relative estrogen defi-
ciency and adjusted her estrogen dose. This
resulted in no change in symptoms. Ancillary
testing included a brain magnetic resonance
image showing nonspecific changes. Further
complete blood count, chemistry panel, and
thyroid studies were also normal. Still lacking
a clear diagnosis, KB decided to increase her
daily kelp supplementation to at least four
pills per day. At this point, she first noticed
gastrointestinal (GI) symptoms including
diarrhea, nausea, and vomiting without
hematemesis. She developed daily pressure
headaches as if “there was a band around her
head.” Additionally, she became excessively
weak and fatigued as the day progressed,
requiring more sleep than previously. By the
summer of 2003, she noticed a lacy, erythe-
matous rash on her lower legs bilaterally.
Other dermatologic findings included
onchyolysis. Physical ﬁndings were conﬁrmed
on dermatologic assessment, which yielded a
diagnosis of onchomycosis. An antifungal was
prescribed but was of no beneﬁt to her condi-
tion. By the summer of 2003, the debilitating
nature of her symptoms forced her to leave
her full-time job and take part-time work. 
Her physician believed that her symptoms
resembled those of a patient he had previously
seen with arsenic toxicity. On 9 October
2003, a spot urine sample showed an arsenic
concentration of 83.6 µg/g creatinine (normal
< 50 µg/g creatinine). No lead or mercury was
detected.
A detailed exposure history focusing on
potential sources of arsenic was conducted.
KB’s home water is from a deep well that was
found to contain arsenic below detectable lev-
els. Her diet consisted of less than one serving
of seafood/ﬁsh per week. A sample of the kelp
supplement was analyzed by Columbia
Analytic Services (Kelso, WA) and showed an
arsenic concentration of 8.5 mg/kg. No arsenic
was detected in the ﬁsh oil she had been tak-
ing. The ginkgo biloba and grape seed extract
were not analyzed. 
Given the arsenic contamination in the
kelp supplement, her physician recommended
that she stop taking the supplement. She noted
a dramatic improvement in her neurologic,
GI, and dermatologic symptoms. Three weeks
after stopping supplement use, KB returned to
full-time work on 1 November 2003, with
nearly complete resolution of symptoms.
Repeat spot urine arsenic on 10 December
2003, was 25 µg/L (normal 0–50 µg/L), down
over one-third from 2 months before. In a
urine sample analyzed on 26 February 2004,
arsenic was undetectable. Blood arsenic on
26 February 2004, was 8 µg/L (normal for
reporting laboratory, 2–23). 
Discussion
Clinical manifestations of chronic arsenic
exposure. Chronic arsenic toxicity may cause
peripheral neuropathies, parasthesia, ataxia,
cognitive deficits, fatigue, and muscular
weakness. GI complaints include anorexia,
hepatomegaly, jaundice, nausea, and vomiting.
Skin afﬂictions may include erythema, eczema,
pigmentation (arsenic melanosis), diffuse
alopecia, keratosis (especially of palms and
soles), scaling and desquamation, brittle nails,
white lines or bands in the nails (Mees lines),
and localized subcutaneous edema. White
striae in the fingernails are consistent with a
diagnosis of arsenical polyneuritis, even though
urine and hair arsenic concentrations may be
within normal limits (Heyman et al. 1956).
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CONTEXT: Medicinal use of dietary herbal supplements can cause inadvertent arsenic toxicosis.
CASE PRESENTATION: A 54-year-old woman was referred to the University of California, Davis,
Occupational Medicine Clinic with a 2-year history of worsening alopecia and memory loss. She
also reported having a rash, increasing fatigue, nausea, and vomiting, disabling her to the point
where she could no longer work full-time. A thorough exposure history revealed that she took daily
kelp supplements. A urine sample showed an arsenic level of 83.6 µg/g creatinine (normal
< 50 µg/g creatinine). A sample from her kelp supplements contained 8.5 mg/kg (ppm) arsenic.
Within weeks of discontinuing the supplements, her symptoms resolved and arsenic blood and
urine levels were undetectable.
DISCUSSION: To evaluate the extent of arsenic contamination in commercially available kelp, we
analyzed nine samples randomly obtained from local health food stores. Eight of the nine samples
showed detectable levels of arsenic higher than the Food and Drug Administration tolerance level of
0.5 to 2 ppm for certain food products. None of the supplements contained information regarding
the possibility of contamination with arsenic or other heavy metals. The 1994 Dietary Supplement
Health and Education Act (DSHEA) has changed the way dietary herbal therapies are marketed
and regulated in the United States. Less regulation of dietary herbal therapies will make inadvertent
toxicities a more frequent occurrence.
RELEVANCE TO CLINICAL PRACTICE: Clinicians should be aware of the potential for heavy metal
toxicity due to chronic use of dietary herbal supplements. Inquiring about use of dietary supple-
ments is an important element of the medical history.
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18 January 2007]Manifestations of chronic arsenic inges-
tion depend on both the intensity and dura-
tion of exposure. Our case had a more severe
presentation than would be expected with an
elevated urinary arsenic concentration of
83.6 µg/g creatinine. The intensity of her
symptoms may have been the result of her
lengthy duration of exposure or perhaps of an
undiagnosed underlying condition. Also, that
a single spot urine may not be as accurate as a
24-hr urine sample, despite adjustment for
creatinine concentration.
In most cases the toxic moiety is presum-
ably trivalent arsenic in the form of inorganic
arsenious acid (arsenite), or an organic
arsenoxide, rather than the element itself.
Pentavalent arsenicals may be reduced, to a
small extent in vivo, to the active trivalent
form. This in vivo conversion may explain
why all chemical forms of arsenic eventually
produce the same toxic syndrome.
Dietary sources of arsenic. Elemental
arsenic is found naturally in the earth’s crust
at concentrations of 2–5 ppm (Tamaki and
Frankenberger 1992). Arsenic is released into
the environment through both natural
sources (i.e., soil erosion, volcanoes) as well as
anthropogenic sources (e.g., release from
metal mining and smelting, pesticide applica-
tion, coal combustion, waste incineration).
Most arsenic release into the environment is
inorganic and accumulates by binding to
organic soil matter (Smedley and Kinniburgh
2005).
Soils with high arsenic concentrations can
yield foods with exceedingly elevated arsenic
levels. Diet is the largest source of exposure
for nonoccupationally exposed individuals,
with an average total (inorganic and methy-
lated) arsenic intake of 40 µg/day. U.S.
dietary intake of inorganic arsenic has been
estimated to range from 1 to 20 µg/day
(Schoof et al. 1999). Because of high arsenic
concentration in algae and marine micro-
organisms, seafood is the highest dietary
source of arsenic (Tao and Bolger 1999).
Arsenic concentrations for fish and seafood
average 4–5 ppm (Bennett 1981), signi-
ficantly higher than concentrations found
in grains and cereals, with an average of
0.02 ppm (Gartrell et al. 1986). Although
chronic low-level exposure to arsenic does
occur from dietary sources, it is usually
signiﬁcantly below toxic levels. The tragedy of
acute and chronic arsenic poisoning from
contamination of water in Bangladesh, West
Bengal, and elsewhere in the world has
recently been described (Mead 2005).
Homeopathic medications and arsenic
toxicity. A number of published studies have
highlighted cases in which homeopathic
remedies cause clinical arsenic toxicity. One
such study describes 74 patients in Singapore
who were victims of chronic arsenic poisoning
caused by local antiasthmatic herbal prepara-
tions (Tay and Seah 1975). Systemic involve-
ment mainly affected the patients’ skin
(hyperpigmentation, hyperkeratosis), nervous
system (polyneuropathy, tremors, headache),
and GI system (gastroenteritis, toxic hepatitis).
Of the 74 patients studied, 10 presented with
malignancies. Of the 29 herbal preparations
analyzed in this study, 16 contained inorganic
arsenic in concentrations of 25–1,000 ppm,
and 10 contained 1,001–50,000 ppm.
Mitchell-Heggs et al. (1990) reported on a
33-year-old Korean woman who presented
with malaise, difﬁculty walking, arthralgia, and
diarrhea. Her elevated urine and blood arsenic
levels were linked to an herbal treatment for
hemorrhoids, which contained 10,000 ppm
arsenic. The patient recovered completely after
ceasing her usual dosage of 90 pills/day
(50 mg/day). 
Espinoza et al. (1995) analyzed traditional
Chinese herbal balls, which are taken for a
variety of conditions, including rheumatism
and cataracts. The herbal balls were found to
contain up to 36.6 mg arsenic per ball. The
authors concluded that with a “recommended
dose” of two herbal balls daily, the preparation
“poses a potentially serious health risk to con-
sumers.” They advised that “health profession-
als should be aware that patients who consume
traditional Chinese remedies may be exposed
to potentially toxic substances” (Espinoza
et al. 1995).
To our knowledge, only one case study
has previously documented arsenic toxicity
related to consumption of herbal kelp supple-
ments. Walkiw and Douglas (1975) reported
on two patients admitted for neurologic
investigation with elevated urinary arsenic
excretion (138 and 293 µg/24 hr). Through
detailed history and laboratory sampling,
both cases were linked to ingestion of kelp
supplement. Urinary arsenic concentrations
declined to normal range (< 10 µg/24 hr)
within 3 months of discontinuing kelp sup-
plements. The initial presenting signs of foot-
drop also resolved. 
Laboratory data. To assess the concentra-
tion of arsenic present in commercially avail-
able kelp supplements, we purchased nine
over-the-counter kelp samples from local
health food outlets. Included were samples
from three different batches of the product
that was consumed by the patient. We deter-
mined total arsenic in the herbal samples by
inductively coupled argon plasma (ICP) using
the identical hydride vapor generation
method, as described by Tracy et al. (1991).
The ICP used was an Applied Research
Laboratories–model Accuris, and ﬁtted with a
Noordermeer V-groove nebulizer (both from
Fisons Instruments, Valencia, CA). All
samples were analyzed randomly in a blind-
folded manner.
Laboratory analysis by the California
Animal Health & Food Safety Laboratory
found detectable levels of arsenic in eight of
the nine kelp herbal supplements, ranging
from 1.59 ppm to 65.5 ppm by dry weight
(1.59, 2.28, 9.55, 9.97, 10.5, 24.1, 34.8, and
65.5 ppm); the median value was 10.23 ppm.
One of the nine samples was below the
method detection limit of 0.010 ppm. The
three samples of the brand of kelp supple-
ment consumed by our patient throughout
the duration of her symptoms showed arsenic
concentrations of 34.8, 2.28, and 1.59 ppm. 
In a recent analysis of ayurvedic herbal
medicine products, Saper et al. (2004) found
that 20% of products tested contained heavy
metals. Detectable arsenic levels in 6 of
70 samples ranged in concentrations from
37 ppm to 8,130 ppm. Although the kelp sam-
ples we analyzed were consistently elevated, the
concentration of arsenic in our samples was
considerably lower than previously docu-
mented concentrations in herbal remedies
(Mitchell-Heggs et al. 1990; Saper et al. 2004;
Tay and Seah 1975). This raises the concern
that chronic exposure to contaminated supple-
ments, even with moderately elevated arsenic
concentrations, could still be toxic. None of
the supplements contained labeling informa-
tion regarding the possibility of contamination
with arsenic or other heavy metals. 
The Food and Drug Administration
(FDA) has set tolerance levels for arsenic in
certain food products. These permissible levels
range from 0.5 ppm in eggs and uncooked
edible tissues of chickens and turkeys to
2 ppm in certain uncooked edible by-products
of swine. The concentration of arsenic found
in seven of the nine supplements exceeded the
FDA tolerance level of 2 ppm (Agency for
Toxic Substances and Disease Registry 2006). 
Regulation and standards of homeopathic
remedies. In 1998, the California Department
of Health reported that 32% of traditional
Asian medicines sold in the state contained
heavy metals (including lead, mercury, and
arsenic) or undeclared pharmaceuticals (Ko
1998). Although this case report focuses on
the potential for arsenic contamination in
herbal supplements, lead exposure from sup-
plements is also of increasing concern (Mattos
2006). Labeling information provides little
warning; two-thirds of homeopathic medi-
cines sampled contained arsenic levels higher
than indicated on the label (Kerr and Saryan
1986).
The popularity of herbal treatments and
dietary supplements has increased at an aston-
ishing rate. In 2001, $178 billion was spent
in the United States on dietary supplements
(Anonymous 2002). Of the many reasons for
the increasing popularity of supplements, the
most important has been attributed to the
enactment of the Dietary Supplement and
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Health Education Act (DSHEA 1994;
Marcus and Grollman 2002). DSHEA
amends the Food and Drug Act (1938) to
deﬁne the way dietary supplements are regu-
lated and labeled. Under DSHEA (1994),
herbal, vitamin, and mineral treatments are
considered dietary supplements, and the act
limits the FDA’s control over substances clas-
siﬁed as dietary supplements.
Commenting on DSHEA, former FDA
commissioner David A. Kessler stated that 
[T]he Act does not require that dietary supple-
ments be shown to be safe or effective before they
are marketed. The FDA does not scrutinize a
dietary supplement before it enters the market-
place. (Kessler 2000)
Instead, Kessler noted, the FDA must rely on
adverse event reports to determine product
safety and efﬁcaciousness. As a result, dietary
supplements such as herbal therapies are now
subject to lower safety standards than food
additives. In a review of regulations for botan-
ical medicines, Mitchell-Heggs et al. (1990)
warned that 
Consumers are provided with more information
about the composition and nutritional value of a
loaf of bread than about the ingredients and poten-
tial hazards of botanical medicines. 
Conclusion
Heavy metal intoxication should be sus-
pected in a patient presenting with idiopathic
neuropathy. When neuropathy is accompa-
nied by an elevated urinary arsenic level, it is
crucial that the physician determine the
source of the arsenic (Walkiw and Douglas
1975). Our patient, KB, had complete reso-
lution of her symptoms and was able to
return to work within weeks of discontinuing
her kelp supplements. Her urine arsenic lev-
els returned to normal within 2 months of
the initial diagnosis. Given the nature of her
symptoms and the temporal association of
her kelp ingestion with the occurrence and
resolution of the symptoms (an association
supported by urinary arsenic levels, which
were elevated as her kelp ingestion increased),
we believe that there was a causal association
between her ingestion and symptoms. There
was also clear biological plausibility in this
case; arsenic is known to cause the symptoms
observed in our patient, and previous studies
have demonstrated toxicity from intake of
dietary herbal supplements. We were unable
to identify any other probable dietary or
environmental exposure. We recognize, how-
ever, that the estimated dose of her exposure
in this case was based on limited analyses,
and was therefore approximate. 
Our finding that eight of the nine
commercially available kelp supplements con-
tained detectable levels of arsenic is a cause for
concern. It appears from our results that there
is little consistency in the arsenic content of
the kelp supplements from batch to batch.
Three samples, all the same brand, showed
variability in contamination ranging from
1.59 ppm to 34.8 ppm arsenic. It is unlikely
that people are aware of the potential
exposures they receive from herbal supple-
ments. Not one of these products had labels
indicating the possibility of arsenic or other
heavy metals in the kelp. It is unfortunate
that a therapy which is advertised (on the
label) as contributing to “vital living and well-
being” would have potentially unsafe levels
of arsenic. 
Given the numerous studies demonstrat-
ing unsafe levels of heavy metals in dietary
herbal preparations, the growing number of
case reports connecting heavy metal toxicities
to ingestion of herbal dietary supplements,
and the growing popularity of herbal reme-
dies for self-medication in the general public,
it is prudent that companies demonstrate
safety and efficacy before their products are
placed on the market. Concentrations of
materials contained in the preparations, as
well as expected benefits and potential side-
effects, should be studied, standardized,
monitored, and accurately labeled.
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CORRECTION
In their discussion of the variation of
arsenic content of kelp supplements from
batch to batch in the conclusion of the
original manuscript published online, the
authors stated that three samples they
tested were all from the same bottle.
However, the samples were all the same
brand but not from the same bottle. The
error has been corrected here.